Article
Dr. Jack Cush muses on the news, journal reports, FDA announcements and the 2024 BSR abstracts just released.
All News
Article
An investigational Toll-like receptor (TLR) antagonist was effective in reducing biomarkers and clinical symptoms of systemic lupus erythematosus (SLE) in a pilot trial, evidence that the innate immune system may hold the key to lupus pathophysiology.
Article
Incomplete lupus? Undifferentiated connective tissue disease? Pre-clinical autoimmune disease? During the lupus pod at RheumNow Live 2024, Dr. David Karp discussed the spectrum of autoimmune disease and the confusing terminology that is used with the complex world of early autoimmune disease. He cautioned against the traditional use of phrases such as incomplete lupus or undifferentiated connective tissue disease, which are heterogeneous and poorly defined.
Article
Dr. Jack Cush reviews this past week’s news and journal articles from RheumNow.com.
Article
Machine learning (ML) models were applied to 3 cohorts of lupus nephritis (LN) patients and established algorithms to predict co-infection in LN.
Dr. John Cush
Tweet
Biology and Rx of Lupus Flares
https://t.co/VlaI1PK8X8 https://t.co/oFXqGUvL4b
Dr. John Cush
Tweet
TLR Antagonist in Lupus
An investigational TLR ) antagonist was effective in reducing biomarkers and clinical symptoms of SLE in a pilot trial, evidence that the innate immune system may hold the key to lupus pathophysiology.
https://t.co/QSX3fRXRLs https://t.co/jt5nVer2ZQ
Dr. John Cush
Tweet
ICYMI: What are the Early Stages of Lupus?
https://t.co/2ACuh2WirF
Dr. John Cush
Tweet
Mexican study 202 #SLE pts shows 89 (45.1%) were hospitalized; their profile was they were younger, shorter Dz duration, higher disease activity scores (SLEDAI), and more damage. Hosp were for Dz activity (61%), Renal Dz, infection, drug toxicity (5.6%)https://t.co/3TKb1ck18V https://t.co/om2R3kfpFY
Dr. John Cush
Tweet
Dr. Gabalawy: "How do you know what disease patients will develop in this preclinical autoimmunity state?"
@drdavidkarp ""it's like when weeds pop up in a garden, it's random ...if ACPA Ab pops up, you might have RA, if it's dsDNA, maybe lupus."" #RNL2024 https://t.co/kDkDaDRP8X
Dr. John Cush
Tweet
Low urinary IL16 levels at 12 months predicts kidney survival at 3 years better than proteinuria - @Andreafava @rheumnow #RNL2024 https://t.co/4GLmJQr46C
Dr. John Cush
Tweet
Predicting Infection in Lupus Nephritis
Machine learning (ML) models were applied to 3 cohorts of lupus nephritis (LN) patients and established algorithms to predict co-infection in LN.
https://t.co/BnV7jVfqj1 https://t.co/LYQd6w1DvD
Dr. John Cush
Tweet
Predicting CKD Outcomes in Lupus Nephritis
An observational cohort study suggests that proteinuria levels in lupus nephritis (LN) patients did not predict their histologic class.
https://t.co/UHNqj6WTXn https://t.co/IOc0Gv21FM
Dr. John Cush
Tweet
Venous thromboembolic event Risk study in 1854 SLE pts vs controls (12,107) from 1985–2015 in W Australia. VTE affected 12.8% SLE pts; 6 fold higher than controls (RR 6.6). Risk factors: aPL(aHR 4.24), serositis (2.7), nephritis (1.75), low Plts (1.65) https://t.co/efUUQzTNzK https://t.co/XXXXTbQOCn
Dr. John Cush
Tweet
Predicting CKD Outcomes in Lupus Nephritis
An observational cohort study suggests that proteinuria levels in lupus nephritis (LN) patients did not predict their histologic class.
https://t.co/SCsuYuXgw4 https://t.co/bHB9ggf20H
Dr. John Cush
Tweet
1/3 of lupus nephritis patient classified as ""complete responders"" continued to accrue progressive renal damage despite resolution of proteinuria over 1 year.
Dr. @andreafava reviews GFR trajectories after renal bx at #RNL2024 @RheumNow https://t.co/mqwhfIFQsL
Dr. John Cush
Tweet
#RNL2024
@DrDavidKarp
Incomplete lupus is heterogeneous term
""Stage 2"" pre-classification stage as ILE/UCTD
Stage 1: non-specific antibodies, dysregulation
2: incomplete features
3: classified, multi-system disease
4: irreversible tissue damage https://t.co/lmorwojG49
Dr. John Cush
Tweet
Urine proteomics in lupus nephritis
IL-16 and CD163 are urinary biomarkers most correlated w/ histologic activity
Myeloid & degranulation sign ass w histo activity -> PR3+cells abundant in LN
@andreafava #RNL2024 @RheumNow https://t.co/YpoMiupOlQ
Dr. John Cush
Tweet
Venous thromboembolic event Risk study in 1854 SLE pts vs controls (12,107) from 1985–2015 in W Australia. VTE affected 12.8% SLE pts; 6 fold higher than controls (RR 6.6). Risk factors: aPL(aHR 4.24), serositis (2.7), nephritis (1.75), low Plts (1.65) https://t.co/KNInhNkjmQ https://t.co/jT3cTemxMD
Dr. John Cush
Tweet
Our final TNR for the month of April will take place on 4/30 at 6:30pm ET.
Mastering SLE
Rethinking Pre-Clinical Disease in Lupus - David Karp, MD
Biology and Rx of Lupus Flares - Michelle Kahlenberg, MD
Current/Future Biomarkers in SLE - Andrea Fava, MD
https://t.co/IoRDAaAJbo https://t.co/C7HpKvehXX
